Marina Cerrone
Research Assistant Professor of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.
Year:
2025
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
Year:
2024
Introduction Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine’s notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.
Year:
2024
BACKGROUND: Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. No effective medical therapy is available to prevent or arrest the disease. We tested the hypothesis that adeno-associated virus vector–mediated delivery of the human PKP2 gene to an adult mammalian heart deficient in PKP2 can arrest disease progression and significantly prolong survival. METHODS: Experiments were performed using a PKP2-cKO (cardiac-specific, tamoxifen-activated PKP2 knockout murine model). The potential therapeutic, adeno-associated virus vector of serotype rh.74 (AAVrh.74)-PKP2a (PKP2 variant A; RP-A601) is a recombinant AAVrh.74 gene therapy viral vector encoding the human PKP2 variant A. AAVrh.74-PKP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-activated PKP2-cKO. PKP2 expression was confirmed by molecular and histopathologic analyses. Cardiac function and disease progression were monitored by survival analyses, echocardiography, and electrocardiography. RESULTS: Consistent with prior findings, loss of PKP2 expression caused 100% mortality within 50 days after tamoxifen injection. In contrast, AAVrh.74-PKP2a–mediated PKP2a expression resulted in 100% survival for >5 months (at study termination). Echocardiographic analysis revealed that AAVrh.74-PKP2a prevented right ventricle dilation, arrested left ventricle functional decline, and mitigated arrhythmia burden. Molecular and histological analyses showed AAVrh.74-PKP2a–mediated transgene mRNA and protein expression and appropriate PKP2 localization at the cardiomyocyte intercalated disc. Importantly, the therapeutic benefit was shown in mice receiving AAVrh.74-PKP2a after disease onset. CONCLUSIONS: These preclinical data demonstrate the potential for AAVrh.74-PKP2a (RP-A601) as a therapeutic for PKP2-related arrhythmogenic right ventricular cardiomyopathy in both early and more advanced stages of the disease.
Year:
2024
Collaborators (48)
Sharlene Day
Associate Professor
University of Pennsylvania
Bryan Cannon
Professor of Pediatrics
Texas Children's Hospital
Arthur A M Wilde
University of Amsterdam
Nisha Gilotra
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Silvana Molossi
Associate Professor, Associate Chief of Cardiology
Baylor College of Medicine
Firat Duru
-
Kristina Haugaa
Professor
University of Oslo
A.s Amin
Cardiologist
Amsterdam University Medical Centers
Eric Smith
University of Michigan
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
J. Peter van Tintelen
Head Department; clinical geneticist
Universitair Medisch Centrum Utrecht
Gregory Webster
Northwestern University Feinberg School of Medicine
Matthew Taylor
Professor
University of Colorado Anschutz Medical Campus
Lia Crotti
Director of the Cardiological Rehabilitation Unit, San Luca Hospital
IRCCS Istituto Auxologico Italiano
Victoria N. Parikh
Stanford University
Sing-Chien Yap
Researcher
Erasmus University Rotterdam
Michela Casella
Researcher
Università Politecnica delle Marche
Mario Delmar
Patricia M. and Robert H. Martinsen Professor of Cardiology and Professor of Cell Biology
NYU School of Medicine
Belinda Gray
University of Sydney
Elijah R Behr
Director
University College London
Adam Helms
Assistant Professor
University of Michigan
Maria Teresa Tome Esteban
Consultant cardiologist and Professor of Practice_ cardiology
St George’s, University of London
Petros Syrris
University College London
James Ware
Professor
Imperial College London
Marco Merlo
University of Trieste
Brian Olshansky
Electrophysiologist
-
Gianfranco Sinagra
University of Trieste
Barbara Bauce
Associate Professor
University of Padova
Hugh Calkins
Johns Hopkins University School of Medicine
Cynthia James
Associate Professor
Johns Hopkins University
cristina basso
Professore Ordinario di Anatomia Patologica
University of Padova
Kalliopi Pilichou
Associate Professor
University of Padua
Ardan M. Saguner
-
Susan P Etheridge
-
Katie Stiles
Assistant Professor of Research
Weill Cornell Medical College
Wojciech Zareba
Professor of Medicine/Cardiology
University of Rochester Medical Center
Anthony Aizer
Assistant Professor (Clinical) of Medicine (Academic)
NYU School of Medicine
Luisa Mestroni
Professor of Medicine
University of Colorado Anschutz Medical Campus
Juan Gimeno Blanes
Associate Professor
Universidad de Murcia
Kimberly Harmon
Professor
University of Washington
Marco Schiavone
Clinical Scientist
Centro Cardiologico Monzino
Prince Kannankeril
Professor
Vanderbilt University Medical Center
Shubhayan Sanatani
Professor
The University of British Columbia
Rachel Lampert
Yale University School of Medicine
David Park
Associate Professor of Medicine
NYU School of Medicine
Giovanni Peretto
Vita-Salute San Raffaele University
Perry Elliott
University College London
Ilan Goldenberg
-
Make your next move.
Prepare your application
Review drafts before you send them.